Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Galli

Showing results (101-110 of 179) with videos related to

Pageof 18
Sort By:
Nuclear Medicine Communications|August 13, 2005
Patients with known or suspected lung cancer: evaluation of clinical management changes due to 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) studyGino Pepe, Claudio Rossetti, Sandro Sironi, et al.
AIDS (London, England)|August 28, 2014
Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapyLaura Galli, Vincenzo Spagnuolo, Andrea Poli, et al.
AIDS (London, England)|March 22, 2006
Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study)Antonella Castagna, Anna Danise, Stefano Menzo, et al.
Plos One|February 17, 2018
Long-term efficacy and safety of rilpivirine plus abacavir and lamivudine in HIV-1 infected patients with undetectable viral loadNadia Galizzi, Laura Galli, Andrea Poli, et al.
The Journal of Antimicrobial Chemotherapy|August 9, 2007
Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairmentElena Seminari, Anna De Bona, Gianluca Gentilini, et al.
Journal of the International AIDS Society|August 2, 2015
Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapyNicola Gianotti, Andrea Poli, Silvia Nozza, et al.
AIDS (London, England)|June 29, 2012
Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimensAlba Bigoloni, Nicola Gianotti, Vincenzo Spagnuolo, et al.
Medicine|September 8, 2016
High-density lipoprotein-cholesterol levels and risk of cancer in HIV-infected subjects: Data from the ICONA Foundation CohortNicola Squillace, Laura Galli, Alessandra Bandera, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 12, 2018
Brief Report: Hyperbilirubinemia Is Associated With a Decreased Risk of Carotid Atherosclerosis in HIV-Infected Patients on Virological SuppressionCamilla Muccini, Laura Galli, Andrea Poli, et al.
Journal of Medical Virology|July 10, 2019
Homeostatic model assessment for insulin resistance index trajectories in HIV-infected patients treated with different first-line antiretroviral regimensNicola Gianotti, Camilla Muccini, Laura Galli, et al.
Pageof 18

Showing results (101-110 of 179) with videos related to

Sort By:
Pageof 18
Nuclear Medicine Communications|August 13, 2005
Patients with known or suspected lung cancer: evaluation of clinical management changes due to 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) studyGino Pepe, Claudio Rossetti, Sandro Sironi, et al.
AIDS (London, England)|August 28, 2014
Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapyLaura Galli, Vincenzo Spagnuolo, Andrea Poli, et al.
AIDS (London, England)|March 22, 2006
Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study)Antonella Castagna, Anna Danise, Stefano Menzo, et al.
Plos One|February 17, 2018
Long-term efficacy and safety of rilpivirine plus abacavir and lamivudine in HIV-1 infected patients with undetectable viral loadNadia Galizzi, Laura Galli, Andrea Poli, et al.
The Journal of Antimicrobial Chemotherapy|August 9, 2007
Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairmentElena Seminari, Anna De Bona, Gianluca Gentilini, et al.
Journal of the International AIDS Society|August 2, 2015
Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapyNicola Gianotti, Andrea Poli, Silvia Nozza, et al.
AIDS (London, England)|June 29, 2012
Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimensAlba Bigoloni, Nicola Gianotti, Vincenzo Spagnuolo, et al.
Medicine|September 8, 2016
High-density lipoprotein-cholesterol levels and risk of cancer in HIV-infected subjects: Data from the ICONA Foundation CohortNicola Squillace, Laura Galli, Alessandra Bandera, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 12, 2018
Brief Report: Hyperbilirubinemia Is Associated With a Decreased Risk of Carotid Atherosclerosis in HIV-Infected Patients on Virological SuppressionCamilla Muccini, Laura Galli, Andrea Poli, et al.
Journal of Medical Virology|July 10, 2019
Homeostatic model assessment for insulin resistance index trajectories in HIV-infected patients treated with different first-line antiretroviral regimensNicola Gianotti, Camilla Muccini, Laura Galli, et al.
Pageof 18